Open an account

NextCure

NXTC · NASDAQ

$5.44−$0.23 (−4.06%)TodayMarket closed ·
Prev close $5.67

About NXTC

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 40 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Employees
40
Headquarters
Beltsville, Maryland
Listed
May 9, 2019
Sector
Health Care
Industry
Biotechnology
Website
nextcure.com

NXTC key statistics

Market cap
24.90M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
91.86K
Volume
82.12K
Open price
$5.87
High today
$6.10
Low today
$5.33
52 Week high
$15.74
52 Week low
$1.55

NextCure (NXTC) at a glance

NextCure (NXTC) last traded at $5.44, with a market cap of 24.90M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.33 and $6.10. The current price is 2.1% above the day's low and 10.8% below its high.

Volume so far is 82.12K shares, in line with the average of 91.86K shares a day.

Over the past year NextCure has ranged from $1.55 to $15.74, and now sits 27% of the way up that range.

NextCure met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$2.80 per share against an estimate of -$1.97.

The average analyst price target is $20.40, 275.0% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $20.40
Low
$20.20
Now
$5.44
High
$21.00

NXTC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 26.3% on average.

  1. Q3 FY24: reported -$4.92 per share against an estimate of -$4.22
  2. Q4 FY24: reported -$4.92 per share against an estimate of -$4.10
  3. Q1 FY25: reported -$4.68 per share against an estimate of -$4.90
  4. Q2 FY25: reported -$11.29 per share against an estimate of -$4.71
  5. Q3 FY25: reported -$3.22 per share against an estimate of -$4.06
  6. Q4 FY25: reported -$0.81 per share against an estimate of -$2.46
  7. Q1 FY26: reported -$1.87 per share against an estimate of -$2.15
  8. Q2 FY26: reported -$2.80 per share against an estimate of -$1.97

NXTC news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releasePRNewswire

    Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releasePRNewswire

    Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB

  • Press releasePRNewswire

    Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?

  • Vandana Singh

    Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy

Similar companies

Companies in the same industry as NextCure

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.